Summary CTLA‐4 and PD‐1 play a key role in tumor‐induced downregulation of
lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the …

Summary CTLA‐4 and PD‐1 are potential targets for tumor‐induced downregulation of
lymphocytic immune responses. Immune checkpoint‐modifying monoclonal antibodies …

Cytotoxic T‐lymphocyte associated protein‐4 (CTLA‐4) and the Programmed Death
Receptor 1 (PD‐1) are immune checkpoint molecules that are well‐established targets of …

Immune checkpoint-blocking antibodies that enhance the immune system's ability to fight
cancer are becoming important components of treatment for patients with a variety of …

Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-
1 have recently obtained approval for the treatment of metastatic melanoma and …

9012^ Background: CTLA-4 and PD-1 are critical immune checkpoint receptors. In MEL pts,
ipilimumab (anti-CTLA-4) prolonged survival in two phase III trials, and nivolumab (anti-PD …

Highlights•Immunity against cancer is negatively regulated by lymphocyte surface
receptors.•Cellular immunity against cancer can be unleashed by mAbs acting on such …

Immunotherapy has emerged as an exciting strategy for cancer treatment. Therapeutic
blockade of immune checkpoint regulators favors the ability of T cell responses to increase …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, yielding
significant antitumor responses across multiple cancer types. Combination ICI therapy with …

Immune checkpoint blockade with monoclonal antibodies directed at the inhibitory immune
receptors CTLA-4, PD-1, and PD-L1 has emerged as a successful treatment approach for …